- Home
- PODC vs ACET Comparison
PODC vs ACET Comparison
Compare PODC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- ACET
- Stock Information
- Founded
- PODC 2013
- ACET 1947
- Country
- PODC United States
- ACET United States
- Employees
- PODC N/A
- ACET N/A
- Industry
- PODC
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- ACET Health Care
- Exchange
- PODC Nasdaq
- ACET Nasdaq
- Market Cap
- PODC 42.8M
- ACET 49.3M
- IPO Year
- PODC N/A
- ACET N/A
- Fundamental
- Price
- PODC $1.50
- ACET $0.66
- Analyst Decision
- PODC
- ACET Strong Buy
- Analyst Count
- PODC 0
- ACET 7
- Target Price
- PODC N/A
- ACET $5.60
- AVG Volume (30 Days)
- PODC 62.2K
- ACET 557.0K
- Earning Date
- PODC 08-13-2025
- ACET 08-07-2025
- Dividend Yield
- PODC N/A
- ACET N/A
- EPS Growth
- PODC N/A
- ACET N/A
- EPS
- PODC N/A
- ACET N/A
- Revenue
- PODC $53,954,000.00
- ACET N/A
- Revenue This Year
- PODC $17.91
- ACET N/A
- Revenue Next Year
- PODC $14.41
- ACET N/A
- P/E Ratio
- PODC N/A
- ACET N/A
- Revenue Growth
- PODC 17.74
- ACET N/A
- 52 Week Low
- PODC $1.10
- ACET $0.45
- 52 Week High
- PODC $2.94
- ACET $1.64
- Technical
- Relative Strength Index (RSI)
- PODC 36.51
- ACET 45.06
- Support Level
- PODC $1.50
- ACET $0.58
- Resistance Level
- PODC $1.69
- ACET $0.70
- Average True Range (ATR)
- PODC 0.16
- ACET 0.05
- MACD
- PODC 0.00
- ACET -0.01
- Stochastic Oscillator
- PODC 8.16
- ACET 39.23
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.